Barclays Downgrades Regenxbio to Equal-Weight, Maintains Price Target to $12
REGENXBIO, Inc.
REGENXBIO, Inc. RGNX | 0.00 |
Barclays analyst Eliana Merle downgrades Regenxbio (NASDAQ:
RGNX) from Overweight to Equal-Weight and maintains the price target from $12 to $12.